AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 201 filers reported holding AGIOS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (20-F)
- Quarterly reports (6-K)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,724,946 | -33.5% | 271,715 | -23.9% | 0.02% | -29.4% |
| Q2 2023 | $10,112,109 | +24.0% | 357,066 | +0.6% | 0.03% | +21.4% |
| Q1 2023 | $8,156,900 | -19.4% | 355,111 | -1.4% | 0.03% | -24.3% |
| Q4 2022 | $10,115,623 | -50.6% | 360,243 | -50.2% | 0.04% | -7.5% |
| Q3 2022 | $20,456,452 | +134.2% | 723,370 | +83.6% | 0.04% | +150.0% |
| Q2 2022 | $8,735,534 | -25.3% | 394,004 | -1.9% | 0.02% | -5.9% |
| Q1 2022 | $11,692,365 | -34.2% | 401,674 | -2.1% | 0.02% | -69.6% |
| Q4 2020 | $17,773,000 | +35.3% | 410,189 | +9.3% | 0.06% | +19.1% |
| Q3 2020 | $13,140,000 | -60.6% | 375,416 | -39.8% | 0.05% | -28.8% |
| Q2 2020 | $33,324,000 | +97.0% | 623,118 | +30.7% | 0.07% | +57.1% |
| Q1 2020 | $16,914,000 | -36.1% | 476,740 | -13.9% | 0.04% | -22.2% |
| Q4 2019 | $26,450,000 | +72.6% | 553,904 | +17.1% | 0.05% | +74.2% |
| Q3 2019 | $15,328,000 | -35.1% | 473,064 | -0.2% | 0.03% | -32.6% |
| Q2 2019 | $23,636,000 | +51.0% | 473,838 | +104.1% | 0.05% | -24.6% |
| Q1 2019 | $15,656,000 | +49.0% | 232,153 | +1.9% | 0.06% | +32.6% |
| Q4 2018 | $10,506,000 | -33.2% | 227,853 | +11.7% | 0.05% | -20.7% |
| Q3 2018 | $15,731,000 | +7.6% | 203,984 | +17.5% | 0.06% | +3.6% |
| Q2 2018 | $14,624,000 | +4.3% | 173,616 | +1.3% | 0.06% | 0.0% |
| Q1 2018 | $14,018,000 | +41.6% | 171,407 | -1.0% | 0.06% | +43.6% |
| Q4 2017 | $9,898,000 | -8.3% | 173,137 | +7.0% | 0.04% | -17.0% |
| Q3 2017 | $10,796,000 | +28.0% | 161,743 | -1.4% | 0.05% | +23.7% |
| Q2 2017 | $8,437,000 | +124.7% | 163,987 | +155.0% | 0.04% | +123.5% |
| Q1 2017 | $3,755,000 | +35.8% | 64,304 | -2.9% | 0.02% | +30.8% |
| Q4 2016 | $2,765,000 | -19.5% | 66,251 | +1.9% | 0.01% | -13.3% |
| Q3 2016 | $3,433,000 | +26.1% | 64,991 | +0.0% | 0.02% | +25.0% |
| Q2 2016 | $2,722,000 | -0.9% | 64,967 | -4.0% | 0.01% | 0.0% |
| Q1 2016 | $2,746,000 | -38.5% | 67,642 | -1.6% | 0.01% | -36.8% |
| Q4 2015 | $4,462,000 | -13.9% | 68,734 | -6.3% | 0.02% | -9.5% |
| Q3 2015 | $5,180,000 | -35.0% | 73,379 | +2.4% | 0.02% | -34.4% |
| Q2 2015 | $7,965,000 | +17.9% | 71,664 | 0.0% | 0.03% | +14.3% |
| Q1 2015 | $6,758,000 | -9.4% | 71,664 | +7.6% | 0.03% | -6.7% |
| Q4 2014 | $7,462,000 | +95.1% | 66,603 | +6.8% | 0.03% | +87.5% |
| Q3 2014 | $3,825,000 | +33.0% | 62,341 | -0.6% | 0.02% | +33.3% |
| Q2 2014 | $2,875,000 | +17.1% | 62,741 | 0.0% | 0.01% | +9.1% |
| Q1 2014 | $2,456,000 | +72.5% | 62,741 | +5.5% | 0.01% | +83.3% |
| Q4 2013 | $1,424,000 | – | 59,473 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |